Abstract
For prostate cancer, the role of dose-escalation (DE) to a biologically equivalent dose (BED) of 200 Gy (at an α/β of 1.5) using conventionally fractionated external beam radiation therapy (CFRT) has been established to improve rates of freedom from biochemical failure (FFBF) vs CFRT with BEDs 200 Gy with high dose rate brachytherapy (HDR-BT) has been postulated to further improve outcomes. The purpose of this study was to determine if increasing BED > 200 Gy with HDR-BT is correlated with outcomes or toxicities.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
